Following adults with suspected cardiac amyloidosis over time with heart scans and exercise tests
Follows adults with suspected cardiac amyloidosis using heart imaging, exercise testing and blood tests.
Key facts
- Who runs it
- Heinrich-Heine University, Duesseldorf
- Where
- Düsseldorf, GermanySee the site
- Trial code
- Registry title
- Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 15 Jun 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Observational
- Record updated
- 11 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are being tested for cardiac amyloidosis, or who already have this diagnosis and have not yet started treatment.
- Age
- Older than 18 years
- Sex
- Men and women
- Disease stage
- Left heart wall thicker than 12 mm on a heart ultrasound, plus at least one "red flag" sign of cardiac amyloidosis (ESC 2021 criteria), or another clear clinical suspicion of amyloidosis.
- Earlier treatment
- People with a confirmed diagnosis must not have started therapy yet.
Main reasons for not taking part
- Cannot have a cardiac MRI (for example metal foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)
- No written informed consent
- Cannot follow the study procedures
- Under 18 years
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age > 18 years
- Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy
- Presence of left ventricular wall thickness > 12 mm on transthoracic echocardiography and at least one "red flag" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis
- Written informed consent
Who cannot take part
- Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)
- Age < 18 years
- Lack of written informed consent for study participation
- Inability to comply with the study procedures
Where in Germany
- University Hospital DuesseldorfDüsseldorf, GermanyContact: Fabian Voß, MDNo longer taking part
About the trial
What the trial wants to find out
Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis
- Plain-language title
- Following adults with suspected cardiac amyloidosis over time with heart scans and exercise testsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 11 May 2026